Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Informed consent comprehension in African research settings.
Afolabi MO, Okebe JU, McGrath N, Larson HJ, Bojang K, Chandramohan D. Afolabi MO, et al. Among authors: larson hj. Trop Med Int Health. 2014 Jun;19(6):625-642. doi: 10.1111/tmi.12288. Epub 2014 Mar 17. Trop Med Int Health. 2014. PMID: 24636078 Free article. Review.
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Köhn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Greenwood B, Leyssen M, Douoguih M, Leigh B, Watson-Jones D; EBL3001 study group. Afolabi MO, et al. Lancet Infect Dis. 2022 Jan;22(1):110-122. doi: 10.1016/S1473-3099(21)00128-6. Epub 2021 Sep 13. Lancet Infect Dis. 2022. PMID: 34529962 Free PMC article. Clinical Trial.
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Köhn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Leyssen M, Greenwood B, Douoguih M, Leigh B, Watson-Jones D; EBL3001 study group. Ishola D, et al. Lancet Infect Dis. 2022 Jan;22(1):97-109. doi: 10.1016/S1473-3099(21)00125-0. Epub 2021 Sep 13. Lancet Infect Dis. 2022. PMID: 34529963 Free PMC article. Clinical Trial.
Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.
Gershman MD, Staples JE, Bentsi-Enchill AD, Breugelmans JG, Brito GS, Camacho LA, Cottin P, Domingo C, Durbin A, Gascon J, Guenaneche F, Hayes EB, Jelenik Z, Khromava A, Martins Rde M, Wilson MM, Massy N, Nasidi A, Niedrig M, Sherwat A, Tsai T, Vilella A, Wilson ME, Kohl KS; Brighton Collaboration Viscerotropic Disease Working Group. Gershman MD, et al. Vaccine. 2012 Jul 13;30(33):5038-58. doi: 10.1016/j.vaccine.2012.04.067. Epub 2012 May 4. Vaccine. 2012. PMID: 22561144 Free PMC article. No abstract available.
Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization.
Amarasinghe A, Black S, Bonhoeffer J, Carvalho SM, Dodoo A, Eskola J, Larson H, Shin S, Olsson S, Balakrishnan MR, Bellah A, Lambach P, Maure C, Wood D, Zuber P, Akanmori B, Bravo P, Pombo M, Langar H, Pfeifer D, Guichard S, Diorditsa S, Hossain MS, Sato Y. Amarasinghe A, et al. Vaccine. 2013 Apr 18;31 Suppl 2:B108-14. doi: 10.1016/j.vaccine.2012.10.119. Vaccine. 2013. PMID: 23598471 Review.
242 results